Literature DB >> 28973110

Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

Matthew P Smeltzer1, Nicholas R Faris2, Meredith A Ray1, Raymond U Osarogiagbon2.   

Abstract

IMPORTANCE: Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination.
OBJECTIVE: To determine whether survival was affected by sequentially more stringent definitions of pN staging quality in a cohort of patients with NSCLC after resection with curative intent.
DESIGN: This observational study used the Mid-South Quality of Surgical Resection cohort, a population-based database of lung cancer resections with curative intent. A total of 2047 consecutive patients who underwent surgical resection at 11 hospitals with at least 5 annual lung cancer resections in 4 contiguous US Dartmouth hospital referral regions in northern Mississippi, eastern Arkansas, and western Tennessee (>90% of the eligible population) were included. Resections were performed from January 1, 2009, through January 25, 2016. Survival was evaluated with the Kaplan-Meier method and Cox proportional hazards models. EXPOSURES: Eight sequentially more stringent pN staging quality strata included the following: all patients (group 1); those with complete resections only (group 2); those with examination of at least 1 mediastinal lymph node (group 3); those with examination of at least 10 lymph nodes (group 4); those with examination of at least 3 hilar or intrapulmonary and at least 3 mediastinal lymph nodes (group 5); those with examination of at least 10 lymph nodes, including at least 1 mediastinal lymph node (group 6); those with examination of at least 1 hilar or intrapulmonary and at least 3 mediastinal nodal stations (group 7); and those with examination of at least 1 hilar or intrapulmonary lymph node, at least 10 total lymph nodes, and at least 3 mediastinal nodal stations (group 8). MAIN OUTCOMES AND MEASURES: N category-stratified overall survival.
RESULTS: Of the total 2047 patients (1046 men [51.1%] and 1001 women [48.9%]; mean [SD] age, 67.0 [9.6] years) included in the analysis, the eligible analysis population ranged from 541 to 2047, depending on stringency. Sequential improvement in the N category-stratified 5-year survival of pN0 and pN1 tumors was found from the least stringent group (0.63 [95% CI, 0.59-0.66] for pN0 vs 0.46 [95% CI, 0.38-0.54] for pN1) to the most stringent group (0.71 [95% CI, 0.60-0.79] for pN0 vs 0.60 [95% CI, 0.43-0.73] for pN1). The pN1 cohorts with 3 or more mediastinal nodal stations examined had the most striking survival improvements. More stringently defined mediastinal nodal examination was associated with better separation in survival curves between patients with pN1 and pN2 tumors. CONCLUSIONS AND RELEVANCE: The prognostic value of pN stratification depends on the thoroughness of examination. Differences in thoroughness of nodal staging may explain a large proportion of intercontinental survival differences. More thorough nodal examination practice must be disseminated to improve the prognostic value of the TNM staging system. Future updates of the TNM staging system should incorporate more quality restraints.

Entities:  

Mesh:

Year:  2018        PMID: 28973110      PMCID: PMC5833630          DOI: 10.1001/jamaoncol.2017.2993

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  26 in total

1.  Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer.

Authors:  Robert A Ramirez; Christopher G Wang; Laura E Miller; Courtney A Adair; Allen Berry; Xinhua Yu; Thomas F O'Brien; Raymond U Osarogiagbon
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

2.  Strategic approach to minimally invasive mediastinal nodal staging-a brave new world?

Authors:  Raymond U Osarogiagbon
Journal:  Lancet Respir Med       Date:  2016-10-20       Impact factor: 30.700

3.  Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database.

Authors:  Raymond U Osarogiagbon; Xinhua Yu
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

4.  Comment on the Proposals for the Revision of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas Faris; Ramón Rami-Porta; Peter Goldstraw; Hisao Asamura
Journal:  J Thorac Oncol       Date:  2016-10       Impact factor: 15.609

5.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

6.  Nonexamination of lymph nodes and survival after resection of non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Xinhua Yu
Journal:  Ann Thorac Surg       Date:  2013-07-30       Impact factor: 4.330

7.  Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer.

Authors:  Matthew P Smeltzer; Nicholas Faris; Xinhua Yu; Robert A Ramirez; Laura E M Ramirez; Christopher G Wang; Courtney Adair; Allen Berry; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2016-06-03       Impact factor: 4.330

8.  Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance).

Authors:  Raymond U Osarogiagbon; Paul A Decker; Karla Ballman; Dennis Wigle; Mark S Allen; Gail E Darling
Journal:  Ann Thorac Surg       Date:  2016-06-02       Impact factor: 4.330

Review 9.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.

Authors:  Hisao Asamura; Kari Chansky; John Crowley; Peter Goldstraw; Valerie W Rusch; Johan F Vansteenkiste; Hirokazu Watanabe; Yi-Long Wu; Marcin Zielinski; David Ball; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

10.  Multi-modality mediastinal staging for lung cancer among medicare beneficiaries.

Authors:  Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2009-03       Impact factor: 15.609

View more
  31 in total

1.  Lymph node micrometastasis in N stage: a call for more evidence.

Authors:  Yijiu Ren; Chenyang Dai; Huikang Xie; Yunlang She; Hang Su; Chang Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

Authors:  Eric M Robinson; Ilkka K Ilonen; Kay See Tan; Andrew J Plodkowski; Matthew Bott; Manjit S Bains; Prasad S Adusumilli; Bernard J Park; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

Review 3.  Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

Authors:  Raymond U Osarogiagbon; Giulia Veronesi; Wentao Fang; Simon Ekman; Kenichi Suda; Joachim G Aerts; Jessica Donington
Journal:  J Thorac Oncol       Date:  2019-03-07       Impact factor: 15.609

4.  Vagus nerve and phrenic nerve guided systematic nodal dissection for lung cancer.

Authors:  Zhenguo Liu; Yao Liu; Chunying Xie; Jiali Yang; Bo Zeng; Sai-Ching Jim Yeung; Chao Cheng
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

5.  Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.

Authors:  Raymond U Osarogiagbon; Nicholas R Faris; Walter Stevens; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale A Akinbobola; Yu-Shen Lee; Meredith A Ray; Matthew P Smeltzer
Journal:  J Thorac Oncol       Date:  2019-11-26       Impact factor: 15.609

6.  Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale Akinbobola; Yu-Sheng Lee; Meghan Meadows; R Samuel Signore; Lynn Wiggins; David Talton; Edmond Owen; Lawrence E Deese; Richard Eubanks; Bradley A Wolf; Paul Levy; E Todd Robbins; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-12-27       Impact factor: 4.330

7.  Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC.

Authors:  Meredith A Ray; Matthew P Smeltzer; Nicholas R Faris; Raymond U Osarogiagbon
Journal:  J Thorac Oncol       Date:  2020-06-20       Impact factor: 15.609

8.  Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.

Authors:  Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Phillip Ojeabulu; Olawale Akinbobola; Meghan Meadows-Taylor; Laura M McHugh; Ahmed M Halal; Paul Levy; Vishal Sachdev; David Talton; Lynn Wiggins; Xiao-Ou Shu; Yu Shyr; Edward T Robbins; Lisa M Klesges
Journal:  J Thorac Oncol       Date:  2021-02-16       Impact factor: 15.609

9.  Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes.

Authors:  Meredith A Ray; Carrie Fehnel; Olawale Akinbobola; Nicholas R Faris; Meghan Taylor; Alicia Pacheco; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  J Thorac Oncol       Date:  2021-02-12       Impact factor: 15.609

10.  Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.

Authors:  Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.